McKesson has agreed to buy Precision Medicine Group for approximately $2.25 billion, expanding its presence in clinical research, drug development, and pharmaceutical commercialization. The McKesson Precision Medicine acquisition marks another major step in the company’s strategy to grow beyond traditional drug distribution and strengthen its higher-growth healthcare businesses.
The $2.25 billion deal will bring Precision Medicine Group’s clinical research, laboratory testing, and commercialization capabilities into McKesson’s business. Once completed, Precision Medicine Group will become part of McKesson’s Oncology & Multispecialty segment, although the company has not announced a specific closing timeline.
Why Is McKesson and Precision Medicine Acquisition Important?
The McKesson and Precision Medicine deal supports the company’s stronger long-term growth potential. McKesson has been reshaping its portfolio by streamlining operations and moving away from some non-core assets while investing more heavily in oncology and specialty care.
Through the McKesson Precision Medicine acquisition, the company gains additional expertise in clinical research and medicine commercialization. This could allow McKesson to play a larger role in supporting drugmakers from the research stage through the launch of new treatments.
“Precision Medicine Group brings complementary capabilities that will enhance our clinical research and commercialization services, strengthen clinical trial execution, and broaden our clinical service offerings,” Stated McKesson CEO Brian Tyler.
What Does Precision Medicine Group Bring to McKesson?
Precision Medicine Group works with biotechnology and pharmaceutical companies to support medicine development and commercialization.
Precision Medicine Group services include:
- Clinical research and clinical trial support
- Laboratory testing
- Complex clinical trial design
- Biomarker identification and intelligence
- Market access and commercialization support
The McKesson Precision Medicine acquisition may therefore help McKesson expand its role within the pharmaceutical development ecosystem rather than operating primarily as a healthcare distribution company.
How Precision Medicine Acquisition Supports McKesson’s Oncology Pipeline?
The Precision Medicine Group’s clinical trial work is heavily concentrated in oncology, or cancer care. It also operates laboratories in the United States and Europe. The Precision Medicine Group acquisition will become part of McKesson’s Oncology & Multispecialty segment after the transaction closes.
The segment has already become an important growth area for the company. Revenue in McKesson’s Oncology & Multispecialty division increased 33% to $14.2 billion in the first quarter of fiscal 2026. The growth reflected expanding services for healthcare providers and specialty distribution activities, including contributions from previous acquisitions.
McKesson’s oncology and multispecialty operations provide services such as specialty provider support, distribution, group purchasing, and practice management. Adding Precision Medicine Group could broaden these capabilities into earlier stages of the medicine lifecycle, including research and development.
What Happens Next In the McKesson and Precision Medicine Deal?
The McKesson Precision Medicine acquisition still needs to move through the completion process, including applicable regulatory scrutiny. McKesson has not provided an expected closing date.
The next key developments in the McKesson and Precision Medicine deal will likely include details about the integration process and how McKesson plans to combine Precision Medicine Group’s capabilities with its existing clinical and specialty healthcare services.
